Overview


According to FutureWise analysis the market for recombinant cell culture supplements in 2023 is US$ 0.52 billion, and is expected to reach US$ 0.84 billion by 2031 at a CAGR of 6.2%.

Cell culture offers essential information pertaining the physiology and biochemistry of cells, which is difficult to comprehend on in vivo conditions. Furthermore, thee methods aid in analysing the effects of drugs on factors like culture conditions, growth rate and population density. Cell culture supplements are important in aiding mammalian cells in producing proteins, which are the crucial ingredients of biologic drugs. Media supplement help in customizing and regulating the cell growth conditions and prolonged maintenance of healthy cells along with improvements in the virality and growth of cells. Many crucial factors are considered during cell supplement addition that includes the state of addition like solution, powder or emulsion supplement components. Recombinant proteins are comprehensively used as cell culture supplements for boosting productivity, growth and consistency. The serum-free cell line are developed with the use of these recombinant proteins.

Rising demand in projects related to cell cultures is one of the major factors responsible for the growth of the market. Furthermore, increased use of animal-free supplements for manufacturing biopharmaceuticals, stem cells and vaccines are some other factors contributing to the recombinant cell culture supplements market growth. Moreover, growing investment in research and development activities in the life science sector shall bolster the proliferation of the market.

  • Thermo Fisher Scientific
  •  Merck KGaA
  •  F. Hoffmann-La Roche Ltd.
  •  Lonza Group Ltd.
  •  Fujiflim Holdings Corporation
  •  Cell Sciences, Inc.
  •  Biocon
  •  InVitria
  •  Stemcell Technologies Inc.
  •  Becton, Dickinson and Company
  •  Abcam plc
  •  Hi-Media Laboratories
  •  Sino Biological
  •  PeproTech
  •  Evercyte GmbH

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  •  Recombinant Growth Factors
    •  Transforming Growth Factor
    •  Epidermal Growth Factor
    •  Platelet-Derived Growth Factors
    •  Fibroblast Growth Factor
    •  Vascular Endothelial Growth Factors (VEGFs)
    •  Interleukins
    •  Recombinant Stem Cell Factor
    •  Other Growth Factors
  •  Recombinant Insulin
  •  Recombinant Albumin
  •  Recombinant Transferrin
  •  Recombinant Trypsin
  •  Recombinant Aprotinin
  •  Recombinant Lysozyme

By Source Type

  •  Animals
  •  Microorganisms
  •  Human

By Application

  •  Stem Cell Therapy
  •  Gene Therapy
  •  Bioprocess Application
  •  Vaccine Development
  •  Others

By End User

  •  Academic and Research Institutes
  •  Biopharmaceutical Companies
  •  Cancer Research Centers
  •  Contract Research Organizations

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa

The market is categorised into product type, source type, application, end user and region. The product type segment is classified into recombinant growth factors, recombinant insulin, recombinant albumin, recombinant transferrin, recombinant trypsin, recombinant aprotinin, recombinant lysozyme and others. The application segment is fragmented into stem cell therapy, gene therapy, bioprocessing application, vaccine development and others. The source type segment is diversified into animals, microorganisms and human. The end user segment is divided into academic and research institutes, biopharmaceutical companies, cancer research centres and contract research organizations.

  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants

  •  Growth prospects
  •  SWOT analysis
  •  Key market trends
  •  Key data-points affecting market growth

  •  To provide with an exhaustive analysis on the global recombinant cell culture supplements market By Product Type, By Source Type, By Application, By End User and By Region
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  •  To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Recombinant Cell Culture Supplements Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Recombinant Cell Culture Supplements Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Recombinant Cell Culture Supplements Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Recombinant Cell Culture Supplements Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Recombinant Growth Factors
         1.1. Transforming Growth Factor
         1.2. Epidermal Growth Factor
         1.3. Platelet-Derived Growth Factors
         1.4. Fibroblast Growth Factor
         1.5. Vascular Endothelial Growth Factors (VEGFs)
         1.6. Interleukins
         1.7. Recombinant Stem Cell Factor
         1.8. Other Growth Factors
        2. Recombinant Insulin
        3. Recombinant Albumin
        4. Recombinant Transferrin
        5. Recombinant Trypsin
        6. Recombinant Aprotinin
        7. Recombinant Lysozyme

  • 8.   Recombinant Cell Culture Supplements Market, By Source Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Animals
        2. Microorganisms
        3. Human

  • 9.   Recombinant Cell Culture Supplements Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Stem Cell Therapy
        2. Gene Therapy
        3. Bioprocess Application
        4. Vaccine Development
        5. Others

  • 10.   Recombinant Cell Culture Supplements Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Academic and Research Institutes
        2. Biopharmaceutical Companies
        3. Cancer Research Centers
        4. Contract Research Organizations

  • 11.   North America Recombinant Cell Culture Supplements Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Recombinant Cell Culture Supplements Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Recombinant Cell Culture Supplements Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Recombinant Cell Culture Supplements Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Thermo Fisher Scientific
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Merck KGaA
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. F. Hoffmann-La Roche Ltd.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Lonza Group Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Fujiflim Holdings Corporation
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Cell Sciences, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Biocon
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. InVitria
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Stemcell Technologies Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. Becton, Dickinson and Company
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
          11. Abcam plc
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
          12. Hi-Media Laboratories
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
          13. Sino Biological
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
          14. PeproTech
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
          15. Evercyte GmbH
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients